Chlorproguanil hydrochloride-dapsone-artesunate
From Wikipedia, the free encyclopedia
 |
This article may be too technical for a general audience. Please help improve this article by providing more context and better explanations of technical details to make it more accessible, without removing technical details. |
Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006. It is being compared against artemether-lumefantrine (Coartem) and against chlorproguanil-dapsone Lapdap. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.[1]
[edit] References
- ^ Das P (2006). "Promising anti-malarial enters phase II studies.". Lancet Infect Dis 6 (9): 551. doi:.
[edit] External links
 |
This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |
